References
- Eidenschink Brodersen L, Alonzo TA, Menssen AJ, et al. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children’s Oncology Group. Leukemia. 2016;30(10):2077–2080.
- Panda D, Chatterjee G, Sardana R, et al. Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. Cytometry B Clin Cytom. 2021;100(2):206–217.
- Barnard DR, Alonzo TA, Gerbing RB, et al. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children’s Oncology Group. Pediatr Blood Cancer. 2007;49(1):17–22.
- de Rooij JD, Branstetter C, Ma J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017;49(3):451–456.
- Masetti R, Bertuccio SN, Pession A, et al. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol. 2019;184(3):337–347.
- Masetti R, Pigazzi M, Togni M, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013;121(17):3469–3472.
- Gruber TA, Larson Gedman A, Zhang J, et al. An inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012;22(5):683–697.
- Thiollier C, Lopez CK, Gerby B, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med. 2012;209(11):2017–2031.
- Thirant C, Ignacimouttou C, Lopez CK, et al. ETO2-GLIS2 hijacks transcriptional complexes to drive cellular identity and Self-Renewal in pediatric acute megakaryoblastic leukemia. Cancer Cell. 2017;31(3):452–465.
- Rossi JG, Rubio P, Alonso CN, et al. Cytoplasmic CD3 expression in infant acute megakaryoblastic leukemia: a new ambiguous lineage subtype? Leuk Res. 2018;71:6–12.
- Alexander TB, Orgel E. Mixed phenotype acute leukemia: current approaches to diagnosis and treatment. Curr Oncol Rep. 2021;23(2):22.
- Giri S, Pathak R, Prouet P, et al. Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia. Blood. 2014;124(25):3833–3834.
- Swerdlow SC, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). Lyon: International Agency for Research on Cancer (IARC); 2017.
- Gaikwad AS, Donohue RE, Elghetany MT, et al. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B-acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2014;7(9):6225–6230.
- Lamble AJ, Eidenschink Brodersen L, Alonzo TA, et al. CD123 expression is associated with high-risk disease characteristics in childhood acute myeloid leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2022;40(3):252–261.
- Foster JH, Williams CL, Elghetany MT, et al. Monozygotic twins with non-Down syndrome associated MLL-rearranged hematologic malignancy and megakaryoblastic differentiation. Leuk Lymphoma. 2019;60(4):1083–1086.
- Smith JL, Ries RE, Hylkema T, et al. Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET pediatric AML study. Clin Cancer Res. 2020;26(3):726–737.
- Woolthuis CM, Park CY. Hematopoietic stem/progenitor cell commitment to the megakaryocyte lineage. Blood. 2016;127(10):1242–1248.